Forte Continues Growth and Support of the Nation’s Leading Cancer Research Institutions

Share Article

Forte Continues to Deliver Best-of-Breed Technology Solutions for Effective Trial Activation and Management

Forte has established itself as not only a leader in the academic clinical research space, but the preferred technology provider for NCI-designated cancer centers and Clinical and Translational Science Award (CTSA) recipients.

Leading healthcare digital transformation platform provider, Forte, today announced its participation at the Association of American Cancer Institutes – Clinical Research Innovation (AACI-CRI) annual meeting, held in Chicago, to discuss strategies and innovative solutions for cancer trial design, activation, management and data analysis. As the leading provider of clinical research technology solutions, Forte continues to expand its footprint and impact on a growing number of the nation’s top cancer centers and academic medical centers. The company remains a valuable strategic partner to researchers, delivering technology solutions that support trusted trial management and operational excellence.

Forte has established itself as not only a leader in the academic clinical research space, but the preferred technology provider for NCI-designated cancer centers and Clinical and Translational Science Award (CTSA) recipients. The last several years of landmark growth have positioned Forte to serve:

  • 73% of NCI-designated cancer centers
  • 40% of CTSA institutions
  • 70% of the top 50 NIH-funded institutions in 2019, including Washington University in St. Louis, University of Michigan Rogel Cancer Center / Michigan Institute for Clinical and Health Research, and Duke University / Duke Cancer Institute
  • 16 Health Care Systems and Hospitals nationwide, including Mount Sinai Health System and MedStar Health

For cancer research especially, Forte’s suite of products has become the de facto standard for enterprise research management (OnCore), regulatory management (Forte eReg), business intelligence (Forte Insights), research evaluation (Forte EVAL) and management of investigator-initiated trials (IITs) (Forte EDC).

“Each institution faces unique challenges and relies heavily on having a technology provider to help navigate challenges, minimize risk and truncate operational inefficiencies,” said Howard H. Bailey, MD, Director of the University of Wisconsin Carbone Cancer Center and a professor of Medicine at the UW School of Medicine and Public Health. “There is no better strategic partner we have in our clinical trial system than Forte. They continue to raise the bar – not only with their solutions but also in what they bring to the table in tangible, strategic value. Forte is a true and trusted partner to us; their work is what allows us to focus on what’s most important, applying innovative science to our patients.”

Forte continues its commitment to extend its technology solutions to meet the evolving needs of research institutions, working closely with industry organizations like AACI, Cancer Center Administrators Forum (CCAF) and the Association of Clinical Research Professionals (ACRP). Forte’s leadership and product innovation teams regularly meet with its Customer Advisory Board (CAB), in which Moffitt Cancer Center & Research Institute, Cedars-Sinai Medical Center and others take part. The CAB sessions focus on discussing clinical trial design, institutional and industry-wide challenges, and the arising needs of participants, researchers, institutions and industry.

“As the needs of research institutions evolve, so does Forte and its approach to developing the solutions that really make an impact for both researcher and participant,” said Shree Kalluri, CEO and Founder at Forte. “We’re proud of the progress we’ve made and remain focused on assisting the science happening now and in the future. Our goal is to work alongside those doing the important research-based work, pushing forward to better understand treatments and discover the cures that will invaluably impact current and future generations.”

About Forte
Forte is the industry-leading provider of software and services in the critical areas of clinical trial management, clinical data management and research administration for cancer centers, academic medical centers and health systems. The company is dedicated to modernizing and standardizing the industry’s approach to clinical research management, execution, and analysis, transforming the way the world studies and treats healthcare.

With a strong belief in community, collaboration and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person, discuss the latest challenges and solutions in clinical research, and discover ways to collaborate to drive meaningful impact to those living with diseases and conditions in need of cures.

Forte continues to be a beacon of information and intelligence to research professionals across the globe, providing complimentary blog articles, eBooks, webinars and more to support continuous learning on industry topics. Learn more at https://forteresearch.com/ and connect with the team at Twitter, LinkedIn, and our resource center.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carol Tong
Visit website